A survey of long-term antiarrhythmic therapy in elderly patients with atrial fibrillation

Australian Journal of Hospital Pharmacy

Volumn 31, Issue 2, 2001, Pages 93-97

  Bajorek, Beata V ^a,c   Krass, Ines ^a   Ogle, Susan J ^b   Duguid, Margaret J ^b   Shenfield, Gillian M ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

^c Faculty of Pharmacy   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIRHEUMATIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIGOXIN; FLECAINIDE; SOTALOL;

AGE; AGED; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; HEART ATRIUM FIBRILLATION; HEART RATE; HEART RHYTHM; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MEDICAL RECORD; PRESCRIPTION; REGRESSION ANALYSIS;

EID: 0034940736     PISSN: 03106810     EISSN: None     Source Type: Journal    
DOI: 10.1002/jppr200131293     Document Type: Article

References (54)

1. Lake FR, Cullen KJ, de Klerk NH, McCall MG, Rosman DL. Atrial fibrillation and mortality in an elderly population. Aust N Z J Med 1989; 19: 321-5.
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med 1987; 147: 1561-4.
3. Srikanth VK, Donnan GA. Management of stroke in older people: a pharmacological perspective. Aust J Hosp Pharm 2000; 30: 60-5.
4. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989; 1: 175-9.
5. Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention in atrial fibrillation study. Final results. Circulation 1991; 84: 527-39.
6. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. N Engl J Med 1990; 323: 1505-11.
7. Connolly SJ, Laupacis A, Gent M, Roberts RS, Carins JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) study. J Am Coll Cardiol 1991; 18: 349-55.
8. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, et al. Warfarin in the prevention of stroke associated with non-rheumatic atrial fibrillation. N Engl J Med 1992; 327: 1406-12.
9. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-57.
10. Bath PMW, Prasad A, Brown MM, MacGregor GA. Survey of use of anticoagulation in patients with atrial fibrillation. BMJ 1993; 307: 1045.
11. Munschauer FE, Priore RL, Hens M, Castilone BA. Thromboembolism prophylaxis in chronic atrial fibrillation-practice patterns in community and tertiary-care hospitals. Stroke 1997; 28: 72-6.
12. Antani MR, Beyth RJ, Covinsky KE, Anderson PA, Miller DG, Cebul RD, et al. Failure to prescribe warfarin to patients with nonrheumatic atrial fibrillation. J Gen Intern Med 1996; 11: 713-20.
13. Nattel S, Hadjis T, Talajic M. The treatment of atrial fibrillation. An evaluation of drug therapy, electrical modalities and therapeutic considerations. Drugs 1994; 48: 345-71.
14. The antiarrhythmic treatment of atrial fibrillation. Drug Ther Bull 1996; 34: 41-5.
15. Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green MPH, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000; 342: 913-20.
16. Brodsky MA, Allen BJ, Walker CJ 3rd, Casey TP, Luckett CR, Henry WL. Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium. Am J Cardiol 1987; 60: 572-5.
17. Gosselink ATM, Crijns HJGM, Van Gelder IC, Hillige H, Wiesfeld ACP, Lie KI. Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA 1992; 267: 3289-93.
18. Rosenbaum MB, Chiale PA, Halpern MS, Nau GJ, Przybylski J, Levi RJ, et al. Clinical efficacy of amiodarone as an antiarrhythmic agent. Am J Cardiol 1976; 38: 934-44.
19. Middlekauff HR, Wiener I, Saxon LA, Stevenson WG. Low-dose amiodarone for atrial fibrillation: time for a prospective study? Ann Intern Med 1992; 116: 1017-20.
20. Middlekauff HR, Wiener I, Stevenson WG. Low-dose amiodarone for atrial fibrillation. Am J Cardiol 1993; 72: 75F-81F.
21. Chun SH, Sager PT, Stevenson WG, Nademanee K, Middlekauff HR, Singh BN. Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. Am J Cardiol 1995; 76: 47-50.
22. Ward DE, Camm AJ, Spurrell RAJ. Clinical antiarrhythmic effects of amiodarone in patients with resistant paroxysmal tachycardias. Br Heart J 1980; 44: 91-5.
23. Gold RL, Haffajee CL, Charos G, Sloan K, Baker S, Alpert JS. Amiodarone for refractory atrial fibrillation. Am J Cardiol 1986; 57: 124-7.
24. Blevins RD, Kerin NZ, Benaderet D, Frumin H, Faitel K, Jarandilla R, et al. Amiodarone in the management of refractory atrial fibrillation. Arch Intern Med 1987; 147; 1401-4.
25. Graboys TB, Podrid PJ, Lown B. Efficacy of amiodarone for refractory supraventricular tachyarrhythmias. Am Heart J 1983; 106: 870-6.
26. Horowitz LN, Speilman SR, Greenspan AM, Mintz GS, Morganroth J, Brown R, et al. Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy. J Am Coll Cardiol 1985; 6: 1402-7.
27. Vitolo E, Tronci M, Larovere MT, Rumolo R, Morabito A. Amiodarone versus quinidine in the prophylaxis of atrial fibrillation. Acta Cardiol 1981; 36: 431-44.
28. Benditt DG, Williams JH, Jin J, Deering TF, Zucker R, Browne K, et al. Maintenance of sinus rhythm with oral d,1-sotalol therapy in patients with symptomatic atrial fibrillation and/or flutter. d,1-Sotalol Atrial Fibrillation/ Flutter Study Group. Am J Cardiol 1999; 84: 270-7.
29. Touboul P, Allot E, Brembilla-Perrot B. Flecainide in the prevention of atrial fibrillation after cardioversion: comparison with quinidine. Circulation 1991; 84: 127.
30. Van Gelder IC, Crijns HJ, Van Gilst WH, Van Wijk LM, Hamer HP, Lie KI. Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. Am J Cardiol 1989; 64: 1317-21.
31. Geraets DR, Kienzle MG. Atrial fibrillation and atrial flutter. Clin Pharm 1993; 12: 721-35.
32. Blackshear JL, Kopecky SL, Litin SC, Safford RE, Hammill SC. Management of atrial fibrillation in adults: prevention of thromboembolism and symptomatic treatment. Mayo Clin Proc 1996; 71: 150-60.
33. Aronow WS. Prevalence of appropriate and inappropriate indications for use of digoxin in older patients at the time of admission to a nursing home. J Am Geriatr Soc 1996; 44: 588-90.
34. Hampton JR. The management of atrial fibrillation in elderly patients. Age Ageing 1999; 28: 249-50.
35. TJ Campbell. Treatment of atrial fibrillation: time for change? Med J Aust 1992; 157: 78-80.
36. Falk RH, Leavitt JI. Digoxin for atrial fibrillation: a drug whose time has gone? Ann Intern Med 1991; 114: 573-5.
37. Falk RH, Knowlton AA, Bernard SA, Gotlieb NE, Battinelli NJ. Digoxin for converting recent-onset atrial fibrillation to sinus rhythm. A randomized, double-blinded trial. Ann Int Med 1987; 106: 503-6.
38. Galun E, Flugelman MY, Glickson M, Eliakim M. Failure of long-term digitalization to prevent rapid ventricular response in patients with paroxysmal atrial fibrillation. Chest 1991; 99: 1038-40.
39. Roberts SA, Diaz C, Nolan PE, Salerno DM, Stapczynski JS, Zbrozek AS, et al. Effectiveness and costs of digoxin treatment for atrial fibrillation and flutter. Am J Cardiol 1993; 72: 567-73.
40. Juul-Moller S, Edvardsson N, Rehnqvist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current cardioversion for atrial fibrillation. Circulation 1990; 82: 1932-9.
41. McCarthy ST, McCarthy GL, John S, Chadwick D, Wollner L. Amiodarone as a treatment for atrial fibrillation refractory to digoxin therapy. Br J Clin Prac 1986 (suppl.); 44: 49-51.
42. National Centre for Classification in Health (NCCH). The international classification of diseases, ninth revision, Australian modification (ICD-9-AM). Sydney: NCCH, Faculty of Health Sciences, University of Sydney; 1995.
43. Lip GYH, Tean KN, Dunn FG. Treatment of atrial fibrillation in a district general hospital. Br Heart J 1994; 71: 92-5.
44. Zarifis J, Beevers G, Lip GYH, Acute admissions with atrial fibrillation in a British multiracial hospital population. Br J Clin Pract 1997; 51: 91-6.
45. McAlister FA, Ackman ML, Tsuyuki RT, Kimber S, Teo KT. Contemporary utilization of digoxin in patients with atrial fibrillation. Ann Pharmacother 1999; 33: 289-93.
46. Final consensus statement of the Royal College of Physicians of Edinburgh. Consensus conference on atrial fibrillation in hospital and general practice, 3-4 September 1998. Br J Haematol 1999; 104: 195-6.
47. Brodsky MA, Chun JG, Podrid PJ, Douban S, Allen BJ, Cygan R. Regional attitudes of generalists, specialists, and subspecialists about management of atrial fibrillation. Arch Intern Med 1996; 156: 2553-62.
48. Stewart FM, Singh Y, Persson S, Gamble GD, Braatvedt GD. Atrial fibrillation: prevalence and management in an acute general medical unit. Aust N Z J Med 1999; 29: 51-8.
49. Lip GYH, Zarifis J, Watson RDS, Beevers DG. Physician variation in the management of patients with atrial fibrillation. Heart 1996; 75: 200-5.
50. Crijns HJ, Van Gelder IC, Van Gilst WH, Hillege H, Gosselink AM, Lie KI. Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter. Am J Cardiol 1991; 68: 335-41.
51. Kusumoto F, Schwartz JB. Antiarrhythmic drugs in the elderly. CVR&R 1993; 23: 11-23.
52. Le Couteur DG, Johnson AG. Drugs and the elderly: prescription idiosyncrasies. Modern Medicine of Australia 1997; Sept: 30-7.
53. The planning and steering committees of the AFFIRM study. Atrial fibrillation follow-up investigation of rhythm management - the AFFIRM study design. Am J Cardiol 1997; 79: 1198-202.
54. McLennan W. Projections of the populations of Australia, states and territories, 1995-2051. Australian Bureau of Statistics. Catalogue No. 3222.0.